Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an update.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an estimated 52% increase in net profit for the first half of 2025, attributed to the acquisition of an additional 10% equity interest in Shanghai Hutchison Pharmaceuticals Limited. This strategic move has allowed the company to consolidate SHPL’s financial results into its own, significantly boosting its earnings and strengthening its market position.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$15.70 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of pharmaceutical products. The company focuses on expanding its market presence and enhancing its product offerings through strategic acquisitions and partnerships.
Average Trading Volume: 6,532,046
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.7B
For a thorough assessment of 2607 stock, go to TipRanks’ Stock Analysis page.